FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2891858409> ?p ?o ?g. }

• W2891858409 abstract "e15021 Background: Regorafenib is a multi-kinase inhibitor that was FDA approved for the treatment of refractory advanced colorectal cancer. It has been found in the clinical trials to have modest benefit and relatively high toxicity, but the outcome of its routine use in the clinic practice is lacking. Our aim is to assess the outcome in our local clinic practice. Methods: Records of all colorectal cases who were treated with regorafenib were reviewed. Structured CRF was developed. Clinical, pathological and molecular data were collected. Efficacy and toxicity details were analyzed. Results: Thirty-two cases of metastatic colorectal cancer were treated with regorafenib from February 2014 to February 2016. All patients received prior oxaliplatin, irinotecan and bevacizumab based regimens, and cetuximab if wild type. Median age: 53.5 years. Male: 15 (46.9%). Primary tumor was right sided in 10 patients (31.3%), and left sided (including rectum) in 22 (68.7%). Pan RAS mutant: 21 (65.6%). Fifteen patients (46.9 %) had ECOG Performance Status of one, whereas 16 patients (50%) have ECOG 2. Starting dose was reduced to 120mg in 11 (34.4%). Only 5 (15.6%) continued beyond 3 cycles. 18 patients (56.3%) required dose reduction. Overall response: PR/CR: zero; Stable disease: 4 (12.5%); Progressive disease: 25 (78.1%); Clinical progression in 1 (3.1%), and 2 cases were not evaluated. After median follow up of 7 months, 22 patients (68.8%) have died, 5 (15.6%) are still alive and 5 (15.6%) are lost to follow up. Median survival: 9.3 months, and median PFS: 2.5 months. Conclusions: Regorafenib has poor tumor response in the routine clinic practice when given to patients with ECOG PS > 1. The median survival in this series is probably overestimated because of the relatively high rate of loss to follow up. Selection of patients is required in the routine clinic practice. Predictive markers are more important for such treatment with modest benefit, and significant toxicity and cost." @default.
• W2891858409 created "2018-09-27" @default.
• W2891858409 creator A5042696306 @default.
• W2891858409 creator A5044661839 @default.
• W2891858409 creator A5056074357 @default.
• W2891858409 creator A5075250255 @default.
• W2891858409 creator A5075408887 @default.
• W2891858409 creator A5090751404 @default.
• W2891858409 creator A5090942420 @default.
• W2891858409 date "2017-05-20" @default.
• W2891858409 modified "2023-09-27" @default.
• W2891858409 title "Outcome of use of regorafenib in metastatic colorectal cancer in routine clinic practice in Saudi Arabia." @default.
• W2891858409 doi "https://doi.org/10.1200/jco.2017.35.15_suppl.e15021" @default.
• W2891858409 hasPublicationYear "2017" @default.
• W2891858409 type Work @default.
• W2891858409 sameAs 2891858409 @default.
• W2891858409 citedByCount "0" @default.
• W2891858409 crossrefType "journal-article" @default.
• W2891858409 hasAuthorship W2891858409A5042696306 @default.
• W2891858409 hasAuthorship W2891858409A5044661839 @default.
• W2891858409 hasAuthorship W2891858409A5056074357 @default.
• W2891858409 hasAuthorship W2891858409A5075250255 @default.
• W2891858409 hasAuthorship W2891858409A5075408887 @default.
• W2891858409 hasAuthorship W2891858409A5090751404 @default.
• W2891858409 hasAuthorship W2891858409A5090942420 @default.
• W2891858409 hasConcept C121608353 @default.
• W2891858409 hasConcept C126322002 @default.
• W2891858409 hasConcept C143998085 @default.
• W2891858409 hasConcept C2776248978 @default.
• W2891858409 hasConcept C526805850 @default.
• W2891858409 hasConcept C71924100 @default.
• W2891858409 hasConceptScore W2891858409C121608353 @default.
• W2891858409 hasConceptScore W2891858409C126322002 @default.
• W2891858409 hasConceptScore W2891858409C143998085 @default.
• W2891858409 hasConceptScore W2891858409C2776248978 @default.
• W2891858409 hasConceptScore W2891858409C526805850 @default.
• W2891858409 hasConceptScore W2891858409C71924100 @default.
• W2891858409 hasLocation W28918584091 @default.
• W2891858409 hasOpenAccess W2891858409 @default.
• W2891858409 hasPrimaryLocation W28918584091 @default.
• W2891858409 hasRelatedWork W2015860205 @default.
• W2891858409 hasRelatedWork W2055294071 @default.
• W2891858409 hasRelatedWork W2258396399 @default.
• W2891858409 hasRelatedWork W2467206133 @default.
• W2891858409 hasRelatedWork W2539804834 @default.
• W2891858409 hasRelatedWork W2588731119 @default.
• W2891858409 hasRelatedWork W2765919915 @default.
• W2891858409 hasRelatedWork W2767743555 @default.
• W2891858409 hasRelatedWork W2808954233 @default.
• W2891858409 hasRelatedWork W2809759086 @default.
• W2891858409 hasRelatedWork W2811168026 @default.
• W2891858409 hasRelatedWork W2889986295 @default.
• W2891858409 hasRelatedWork W2890315255 @default.
• W2891858409 hasRelatedWork W2907682181 @default.
• W2891858409 hasRelatedWork W2909630863 @default.
• W2891858409 hasRelatedWork W2913507829 @default.
• W2891858409 hasRelatedWork W2978975558 @default.
• W2891858409 hasRelatedWork W2996835638 @default.
• W2891858409 hasRelatedWork W3041783666 @default.
• W2891858409 hasRelatedWork W3165945214 @default.
• W2891858409 isParatext "false" @default.
• W2891858409 isRetracted "false" @default.
• W2891858409 magId "2891858409" @default.
• W2891858409 workType "article" @default.